Company news
Ernexa Therapeutics Inc. news in 2024
Ernexa Therapeutics Inc.'s news releases, calls and decks from 2024, newest first.
Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models
December 2, 2024
Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program
November 24, 2024
Eterna Therapeutics Completes Strategic Financial Restructuring with the Aim to Accelerate its Developmental Activities and Long-Term Success
October 29, 2024
Eterna Therapeutics and Factor Bioscience Announce Exclusive License and Collaboration Agreement to Accelerate Cell Therapy Development for Oncology, Autoimmune, and Rare Diseases
October 16, 2024
Eterna Therapeutics Announces Appointment of Mahendra Rao, PhD, to its Scientific Advisory Board
May 7, 2024
Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors
February 19, 2024
Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4)
January 2, 2024